FREE PhD study and funding virtual fair REGISTER NOW FREE PhD study and funding virtual fair REGISTER NOW

Investigation of MHC class II accessory molecule CD74 in human ovarian cancer


   School of Medicine

This project is no longer listed on FindAPhD.com and may not be available.

Click here to search FindAPhD.com for PhD studentship opportunities
  Dr Joseph Kwong, Dr Alan Richardson  No more applications being accepted  Funded PhD Project (Students Worldwide)

About the Project

Survival rate of ovarian cancer patients changed little in the last 40 years, new therapeutic approaches for ovarian cancer are desperately needed. To increase the efficacy of immunotherapy, recent studies have focused on targeting a new set of T cell inhibitory receptors in treating cancer, including LAG3. We propose to investigate how CD74, which is shaping the ligand of LAG3, is involved in ovarian tumour progression. Previously, we reported a cytokine called lymphotoxin that was overexpressed in 50% of human ovarian tumours; our data showed that its overexpression 1) promotes ovarian cancer growth and reduces survival of mice bearing ovarian tumours, 2) activates noncanonical NF-kB signalling and upregulates CD74 in ovarian cancer cells, and 3) increases infiltration of LAG3+T lymphocytes in tumour microenvironment. These findings suggested that lymphotoxin overexpression promotes tumour progression by activating noncanonical NF-kB target genes, upregulating CD74 in cancer cells and inducing T cell exhaustion in tumour microenvironment. We hypothesize that CD74, which acts as a regulator for the ligand of LAG3, promotes tumour growth by activating intracellular signalling in cancer cells and/or inducing T cell exhaustion in tumour microenvironment. We will investigate the expression and regulation of CD74 in human ovarian cancer cell lines and clinical ovarian tumour samples. We will also study the biological function(s) of CD74 in cancer progression and its regulation of the LAG3 ligand in cancer cells. Our work may lead to new targeted therapy using anti-CD74 antibody and new immune checkpoint blockade therapy using anti-LAG3 antibody for ovarian cancer patients.

The project provides the opportunity to work closely with researchers at different universities (including The Chinese University of Hong Kong), clinicians and human patient samples/data to address a pertinent clinical question that will likely lead to patient benefit. The studentship will be based at the Guy Hilton Research Centre in Hartshill. However, there will be the occasional need to attend training at Keele University campus.

 Please ensure you quote FMHS_JKJULY2022 in your application, to ensure it is considered for the funded opportunity.

For application, please visit: https://www.keele.ac.uk/study/postgraduateresearch/studentships/investigationofmhcclassiiaccessorymoleculecd74inhumanovariancancer/


Funding Notes

Funding is available to cover 100% UK student tuition fees, stipend, and consumables for 3 years.
Non-UK applicants will be considered if they are able to self-fund any additional tuition fee costs that may exist and can obtain a visa to study in the UK.

How good is research at Keele University in Biological Sciences?


Research output data provided by the Research Excellence Framework (REF)

Click here to see the results for all UK universities
Search Suggestions
Search suggestions

Based on your current searches we recommend the following search filters.

PhD saved successfully
View saved PhDs